{"name":"Insmed Incorporated","slug":"insmed","ticker":"INSM","exchange":"NASDAQ","domain":"insmed.com","description":"Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease;","hq":"Bridgewater, NJ","founded":2002,"employees":"1664","ceo":"Will Lewis","sector":"Rare Disease Pulmonary","stockPrice":116.01,"stockChange":-1.98,"stockChangePercent":-1.68,"marketCap":"$25.1B","metrics":{"revenue":819564032,"revenueGrowth":229.6,"grossMargin":81.8,"rdSpend":771093000,"netIncome":-1276775000,"cash":510445000,"dividendYield":0,"peRatio":314.4,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2005-01-01","label":"MECASERMIN RINFABATE first approved","drug":"MECASERMIN RINFABATE","drugSlug":"mecasermin-rinfabate","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Arikayce patent cliff ($143.4M at risk)","drug":"Arikayce","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MECASERMIN RINFABATE","genericName":"MECASERMIN RINFABATE","slug":"mecasermin-rinfabate","indication":"Laron-type isolated somatotropin defect","status":"marketed"}]}],"pipeline":[{"name":"MECASERMIN RINFABATE","genericName":"MECASERMIN RINFABATE","slug":"mecasermin-rinfabate","phase":"marketed","mechanism":"Recombinant protein","indications":["Laron-type isolated somatotropin defect"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Insmed Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Insmed reported its fourth quarter and full year 2023 financial results, with revenue of $143.4 million and a net loss of $134.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-10-27","type":"deal","headline":"Insmed Announces Exclusive Distribution Agreement with Sandoz for Arikayce in the European Union","summary":"Insmed announced an exclusive distribution agreement with Sandoz for Arikayce in the European Union.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"FDA Approves Arikayce for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease","summary":"The FDA approved Arikayce for the treatment of nontuberculous mycobacterial (NTM) lung disease in adult patients.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPbzEyZ1ljYnVkSXg4RFo0MGQyY1EtUXNMT1JkeWpxUEJDdVRFeWJyanhkWlh6eUpCcHExTWF0TTI1VXNRZDVFdnRXb0x6djJlSDBTR3dGbGlCWl9NYmY2RUFGQzNqQlVVOVZtY1d3enhtS19vVEVzdkVSemRCY1lsOVJpREc5OUxJYm44Um9pQ3B4bkhmRHNTY09lYTJYbFlqSGNmbVpZTWNuNHhBZWhYbmhEUUhOQQ?oc=5","date":"2026-04-01","type":"pipeline","source":"Schaeffer's Investment Research","summary":"Options Bulls Could Be Right About This Pharma Stock - Schaeffer's Investment Research","headline":"Options Bulls Could Be Right About This Pharma Stock - Schaeffer's Investment Research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNTVVXZzhxbUtYVGJ5SXliRmVGcUFtaWIybDRhUDRTZ0RRVGhJWDB6R0M1R3k3QXhRRmVRRVo0MlBwTlFmYjRqTUprOVd5a0FjNE9tVUh5TVVvU0Fqa3kxU2RYWEx4WkNHXzlmY1pXZGRCMzV2ajdkZU1hQnRLcEg0eVBRaldtcFkwallHNDBCNV9EZXpPRDdiRklQU0dhMFpJekdLb3BPMVZabHI0QTRmTDF1d01jbEpFZjJNc19Uaw?oc=5","date":"2026-03-24","type":"regulatory","source":"TradingView","summary":"INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study - TradingView","headline":"INSM Stock Gains After Arikayce Hits Goal in Label Expansion Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAJBVV95cUxPWG11YkM3NGdLeE15V21kSDdqV3pHeGRhWHA3UWIzZ25ReHlGY19MeWplODJxV1pLbHdSUF9JbFFxSGl4T2RBb2w0UUY1WkJ0emozRlNiZm1FOVZkYTExaDVDNW01NGh1WTAwTTdYaU5vRGRsNnRWeG1ucDBraThyYUgyUWVoakRJaVpaUjlvclpBUjlMcVVLcVYwd0owMWJkN3NPMWFOak1PcWkzdHhiVDhOQ00yU2doR21SWWlYTzNDUjh1dm5aampwZGRwdUdURVBjUU13V1J3V3NleDhVUnBGVnh3Ni1KZkRSNW1hNWEtSklYLTdKTnYtbk9jem9nWUh1VTlsVjM2WWIzT21ydA?oc=5","date":"2026-03-24","type":"pipeline","source":"The Globe and Mail","summary":"Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Addus Homecare (ADUS) and Novo Nordisk (NVO) - The Globe and Mail","headline":"Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Addus Homecare (ADUS) and Novo Nordisk (NVO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5ZbGJ3Rm01UjI2MDhqOXZXa2l1Wm1jOUhFMEFSeElzeENVXzM4WWZfMHBDR3hlVFN4a19aSUNGMUhWV0RKenZYS21FR0tBS1VOV2p3ZlR3dHZGQi1wMGfSAWNBVV95cUxOZW1DMlM2dEZVY3BONzVkR1NrU0VObmFaNnd5NFNITGxmVy1WTkp5Sm12OWxoS1VKLWZSSEtZMzdwdl9vLUJuakpISjQ4dWVtdnhuOG1NX3RRRTlsTjRtWWNQN2M?oc=5","date":"2026-03-23","type":"regulatory","source":"Bitget","summary":"INSM shares rise following Arikayce's successful outcome in label expansion trial - Bitget","headline":"INSM shares rise following Arikayce's successful outcome in label expansion trial","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNT0IzamhuZVlRSnIyR3lqMHlJZ1J5M05pX3ktd3lUZFltZ2xHTmo4QkQwV0YzVElWQTRyeU9reHR4TVVGU09tSVFCQXhMMHBuWlpWVVM3bkNTS3p4SGhGc3pDV1dWNjZmNEhQcDdDZmJ6eUtxX1kycXpobjFSR2RCQkg2OWlSX3N4?oc=5","date":"2026-03-01","type":"pipeline","source":"Finviz","summary":"Insmed Incorporated (INSM) Enters 2026 With Momentum - Finviz","headline":"Insmed Incorporated (INSM) Enters 2026 With Momentum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPYVJQa2lJblU1eHJIcWw2SHpRUmJ0M1lxUE9uREdMNkx1WVJpUC1QYlVsQlh6ZzNlTkxkLWFvR2hEYzFxTkVqZnpicTQya19fLWpIcDhGNW1XQmZSWDJlWjdtZ3FWTjFYY25udGZvejd2RWRmb0s4TElqdFktSUpCYlFld081bU8yWjI4bDV4dlhENHNwcjJRb3JLcDNybUpTMDBUblJUbWVtQmlUUnY3RUFlcXR2RU9oVjVSYQ?oc=5","date":"2026-02-26","type":"deal","source":"Finviz","summary":"Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In - Finviz","headline":"Why Insmed Incorporated (INSM) is One of the Best Strong Buy Healthcare Stocks to Invest In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNT0V0cEpjZUlqVlFPeXJGTXVQVHo4WmlaNlFrTjBzMnlvZ2VkU19kNC1nb0s0NWNGNS10QkRJMlZ6NlJuNWRFWVhucnZ6bmo4b2FVX2cwMFJvZTZxWGMxV25wS2lWdUNIZGhYRENYNFNiU09sNzczejNSWUdla0hMc3ItUWhRbXVhNm9MY1pTU3hzaUp6LTdfWHNHcTRiZ215Vms4ZUc1WFhzdlo0NFVka09B?oc=5","date":"2025-12-18","type":"trial","source":"TechStock²","summary":"Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts - TechStock²","headline":"Insmed Stock (NASDAQ: INSM) Slides on Brensocatib Sinus-Trial Failure; Analysts Reset Forecasts - TechStock²","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE5zcnB0U0xtZGtqcUtIMmRqb2YwX3VvS0pUaXY0aENrNUwtSm1abFk3emhvaWt1MFRqeFRCM3hEdkg0LUhxQU9zWW1XRmVLWGZSM2RfUGRlUUsydi0zMWhfcEtVcEVtLUlkaDFmT0kwNGNfZnVMRTVmeGdCZmJUbG8?oc=5","date":"2025-10-30","type":"pipeline","source":"StocksToTrade","summary":"INSM: On the Rise Again or Just a Bubble? - StocksToTrade","headline":"INSM: On the Rise Again or Just a Bubble?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNaDNQX0psSmpCUkoxNEcxaGUwQ2JOb1hDNzFMX3VUS0N6U0FYbFotNWVRWFhEbWpUWERmSU1UaXc0aFg1Qi1tZ2RWSW9SYS11TnpmRTVaY2RLUW9TcVNSNVlvSF9IYlVBaEl4WGRYaE5pWVpfR3drUTZMYVRNanlpZDEydk5ZLUIzRFNSTUFDUFBoYl9kWXFvMnRELUxfS2hiZWo1dWNZTDFia0haVFpzdkZxZll2U2lxd3c?oc=5","date":"2025-09-30","type":"pipeline","source":"Seeking Alpha","summary":"Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality - Seeking Alpha","headline":"Insmed: De-Risked Respiratory Growth, Premium Multiple, And Real M&A Optionality","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTE5JbC02bkNxaWQ2QXJLOTdYMm9yNUVCcXUtdmllZHN4WGU2aEY3VWstWUlVU3FaREptMVdmZ1BkVE9ydlI2WVh6cXBRb1dNSU5KM2w5NnE3dDZPZVR2M0pndVNkVlQzUGYwRHNIb1kwSkxpVVU3c2dPWE8wVnJIZw?oc=5","date":"2025-09-28","type":"pipeline","source":"Seeking Alpha","summary":"Goldman's 48 potential M&A candidates (INSM:NASDAQ) - Seeking Alpha","headline":"Goldman's 48 potential M&A candidates (INSM:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOTzZzTk90ZFM2Z2NvZUFsOGhfbWJOTWtfRndfSUUzSkpaZU9WRDhYVVh2VWFOQlM5dy02VmkzamFEejRMNEFFRUxnNjVkTFNtRTJyZDNtcWNjSjg1WllpX0txNlZNanlDaS1qd3VSSTNrNzhOMDVfNGktT3ByR21qNHlXLXpLMElVLXkwWVhPcFdFdTVHSmRWS1lYaUhYTDlvdDh3Z2FfUTBRVzFfTGgyZ0s5TkZDcW9GRkJXd0lrdDZJcGtlUlE?oc=5","date":"2025-06-11","type":"pipeline","source":"PR Newswire","summary":"Insmed Announces Pricing of $750 Million Public Offering of Common Stock - PR Newswire","headline":"Insmed Announces Pricing of $750 Million Public Offering of Common Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE8tdUJBQm1XbGZ6NzFBOFRrMUhlZkFrV2VHWnBYaU1ITjVSOEw4QVQ4eFAxc1ZrbEFzaThmekxsRWNuSHAweWJfbE41WkhJdmY4QlM4?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"Insmed Stock Price, News & Analysis - Stock Titan","headline":"Insmed Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"Arikayce","drugSlug":"amikacin-liposome-inhalation-suspension","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":143400000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Vertex Pharmaceuticals","Insight Genetics","Pulmatrix"],"therapeuticFocus":["Rare Diseases","Pulmonary Conditions"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":0,"period":"2017-12-31"},{"value":0,"period":"2017-09-30"},{"value":0,"period":"2017-06-30"},{"value":0,"period":"2017-03-31"},{"value":0,"period":"2016-12-31"},{"value":0,"period":"2016-09-30"}],"grossProfit":112255000,"grossProfitHistory":[{"period":"2025-12-31","value":483485000},{"period":"2024-12-31","value":277965000},{"period":"2023-12-31","value":239635000},{"period":"2022-12-31","value":190232000}],"rdSpend":771093000,"rdSpendHistory":[{"period":"2025-12-31","value":771093000},{"period":"2024-12-31","value":598367000},{"period":"2023-12-31","value":571011000},{"period":"2022-12-31","value":397518000}],"sgaSpend":701167000,"operatingIncome":-994776000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-994776000},{"period":"2024-12-31","value":-786570000},{"period":"2023-12-31","value":-680929000},{"period":"2022-12-31","value":-478123000}],"netIncome":-1276775000,"netIncomeHistory":[{"period":"2025-12-31","value":-1276775000},{"period":"2024-12-31","value":-913772000},{"period":"2023-12-31","value":-749567000},{"period":"2022-12-31","value":-481534000}],"eps":-6.42,"epsHistory":[{"period":"2025-12-31","value":-6.42},{"period":"2024-12-31","value":-5.57},{"period":"2023-12-31","value":-5.34},{"period":"2022-12-31","value":-3.91}],"cash":510445000,"cashHistory":[{"period":"2025-12-31","value":510445000},{"period":"2024-12-31","value":555030000},{"period":"2023-12-31","value":482374000},{"period":"2022-12-31","value":1074036000}],"totalAssets":2264558000,"totalLiabilities":1525582000,"totalDebt":540964000,"equity":738976000,"operatingCashflow":-935014000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-935014000},{"period":"2024-12-31","value":-683882000},{"period":"2023-12-31","value":-536247000},{"period":"2022-12-31","value":-400439000}],"capex":-32561000,"capexHistory":[{"period":"2025-12-31","value":-32561000},{"period":"2024-12-31","value":-21923000},{"period":"2023-12-31","value":-13288000},{"period":"2022-12-31","value":-9878000}],"freeCashflow":-967575000,"dividendsPaid":null,"buybacks":null,"employees":1664,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":212483000,"ebit":-307711000,"ebitda":-302150000,"period":"2025-12-31","revenue":263843000,"epsBasic":-1.54,"netIncome":-328485000,"rdExpense":254911000,"epsDiluted":-1.54,"grossProfit":219623000,"operatingIncome":-249708000},{"sga":186376000,"ebit":-349661000,"ebitda":-345665000,"period":"2025-09-30","revenue":142342000,"epsBasic":-1.75,"netIncome":-370021000,"rdExpense":186415000,"epsDiluted":-1.75,"grossProfit":112977000,"operatingIncome":-261352000},{"sga":154763000,"ebit":-300874000,"ebitda":-297127000,"period":"2025-06-30","revenue":107415000,"epsBasic":-1.7,"netIncome":-321686000,"rdExpense":177190000,"epsDiluted":-1.7,"grossProfit":79340000,"operatingIncome":-253876000},{"sga":147545000,"ebit":-235924000,"ebitda":-232778000,"period":"2025-03-31","revenue":92823000,"epsBasic":-1.42,"netIncome":-256583000,"rdExpense":152577000,"epsDiluted":-1.42,"grossProfit":71545000,"operatingIncome":-229840000},{"sga":142515000,"ebit":-214480000,"ebitda":-211739000,"period":"2024-12-31","revenue":104442000,"epsBasic":-1.32,"netIncome":-235548000,"rdExpense":179727000,"epsDiluted":-1.32,"grossProfit":78291000,"operatingIncome":-245214000}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":116.01,"previousClose":117.99,"fiftyTwoWeekHigh":212.75,"fiftyTwoWeekLow":64.85,"fiftyTwoWeekRange":"64.85 - 212.75","fiftyDayAverage":142.04,"twoHundredDayAverage":155.98,"beta":0.89,"enterpriseValue":25093570560,"forwardPE":314.4,"priceToBook":33.64,"priceToSales":30.68,"enterpriseToRevenue":30.62,"enterpriseToEbitda":-26.44,"pegRatio":0,"ebitda":-949036032,"ebitdaMargin":-115.8,"freeCashflow":-606202112,"operatingCashflow":-895664000,"totalDebt":742462016,"debtToEquity":105.3,"currentRatio":4.47,"returnOnAssets":-31.1,"returnOnEquity":-294.5,"analystRating":"1.2 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":20,"targetMeanPrice":204.75,"targetHighPrice":243,"targetLowPrice":140,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.5,"institutionHeldPercent":105.8,"sharesOutstanding":216752451,"floatShares":194394436,"sharesShort":14709273,"shortRatio":7.27,"shortPercentOfFloat":6.8,"epsTrailing":-5.76,"epsForward":0.37,"revenuePerShare":3.95,"bookValue":3.45,"officers":[{"age":56,"name":"Mr. William H. Lewis J.D., M.B.A.","title":"President, CEO & Chairman"},{"age":44,"name":"Ms. Sara M. Bonstein M.B.A.","title":"Chief Financial Officer"},{"age":56,"name":"Mr. Roger  Adsett M.B.A.","title":"Chief Operating Officer"},{"age":47,"name":"Mr. Michael Alexander Smith J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":61,"name":"Dr. Martina  Flammer M.B.A., M.D.","title":"Chief Medical Officer"},{"age":51,"name":"Mr. Brian K. Kaspar Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Bryan  Dunn","title":"Vice President of Investor Relations"},{"age":null,"name":"Ms. Christie  Camelio","title":"Chief Compliance Officer"}],"industry":"Biotechnology","irWebsite":"http://investor.insmed.com/stockquote.cfm","website":"https://www.insmed.com","phone":"908 977 9900"}}